Orphan designation: vactosertib Treatment of osteosarcoma, 25/07/2023 Positive

Key facts

Metadata

Provider: 

European Medicines Agency

URL: 

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2797

Retrieved on: 

Sunday, February 4, 2024

Information

Tags: 

COMP, IRIS, European Commission, Osteosarcoma, Committee, Patient, EMA, Pharmaceutical industry

Geotags: 

RARE, EU

Summary

Key Points: 

• Key facts
  - Active substance
  - vactosertib
  - Intended use
  - Treatment of osteosarcoma
  - Orphan designation status
  - Positive
  - EU designation number
  - EU/3/23/2797
  - Date of designation
  - Sponsor
  Sirius Regulatory Consulting EU Limited
  Patients' organisations
  For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
  European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
• EU register of orphan medicines
  The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:
  EMA list of opinions on orphan medicinal product designation
  EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:

Copyright: 

2024 European Medicines Agency. All Rights Reserved.